Abstract
Background: Immunotherapy has emerged as an improved systemic treatment in selected patients with advanced hepatocellular carcinoma (HCC). Response rates are achieved in only about a third of patients and survival remains somehow limited, however, occasionally complete response is observed allowing liver resection. The current standard first-line therapy for advanced HCC is a combination of the immune checkpoint and VEGF inhibitors. Herein we report two patients who underwent liver resection after exhibiting good (1 patient) or complete (1 patient) response to this systemic therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
